Egf Articles & Analysis
11 articles found
Growth factors such as epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), keratinocyte growth factor (KGF), vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF), and fibroblast growth factor (FGF) are commonly used in aesthetic applications to promote skin regeneration and repair. ...
In order to make the cells grow well in the serum-free medium, a certain amount of appropriate cytokines, such as EPO, NGF, PDGF, EGF, M-CSF, etc., must be added. Serum-free medium needs to be free of virus contamination, animal-free, stable between batches, etc. ...
Featured products include: CCL1 VEGFR1, IFNA5, IL2, IL4, FGFR1, IL6, TGFB1, CX3CL1, FGF2, TNFA, CXCL1, CSF1, GDF15, C3, EGF, IFNA, C5, IFNA2, IFNA4, IGF1R. More at Creative ...
(2) Aesthetic Medicine Advancements in cell therapy, cytokine therapy, and extracellular matrix therapy have propelled the field of aesthetic medicine. Growth cytokines, such as EGF, bFGF, KGF, VEGF, IGF, and FGF, play a significant role in bio-aesthetic applications, contributing to tissue regeneration and ...
In order to make the cells grow well in the serum-free medium, a certain amount of appropriate cytokines, such as EPO, NGF, PDGF, EGF, M-CSF, etc., must be added. Serum-free medium needs to be free of virus contamination, animal-free, stable between batches, etc. ...
ransforming Growth Factor (TGF) Epidermal growth factor (EGF) EGF acts by binding to the cell surface receptor epidermal growth factor receptor (EGFR). ...
Growth factor (GF) is a group of cytokines that promote the growth and differentiation of corresponding cells, such as nerve growth factor (NGF), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), fibroblast growth factor (FGF), transforming growth factor-β (TGF-β), etc. ...
Today, there are only a few therapies approved to treat COVID-19, but while novel therapies can take decades and billions of dollars to develop, are there opportunities to repurpose existing drugs for new therapies? Our latest whitepaper showcases how CAS Knowledge Graphs reveal new connections and insights that identify drugs to potentially repurpose. Drug repurposing is critical for faster ...
PCSK9 has been shown to bind to the epidermal growth factor-like repeat A (EGF-A) domain of the LDLR; it enhances the degradation of the LDLR by an unknown. ...
To that end, we have utilized a virtual screen approach coupled with cell-based assays to identify small molecule hits against the PCSK9 surface where the LDLR-EGF-A domain binds. The current study focuses on further developments of a new class of antagonists and their role in the regulation of lipoprotein metabolism. ...
In this study, we showed that epidermal growth factor (EGF)-like domain repeats (EGFrp) in stabilin-2 can directly and specifically recognize PS. ...